- Home
- KUKE vs CLRB Comparison
KUKE vs CLRB Comparison
Compare KUKE & CLRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KUKE
- CLRB
- Stock Information
- Founded
- KUKE 2002
- CLRB 2002
- Country
- KUKE China
- CLRB United States
- Employees
- KUKE N/A
- CLRB N/A
- Industry
- KUKE Other Consumer Services
- CLRB Biotechnology: Pharmaceutical Preparations
- Sector
- KUKE Real Estate
- CLRB Health Care
- Exchange
- KUKE Nasdaq
- CLRB Nasdaq
- Market Cap
- KUKE 18.9M
- CLRB 15.3M
- IPO Year
- KUKE 2021
- CLRB N/A
- Fundamental
- Price
- KUKE $0.31
- CLRB $0.31
- Analyst Decision
- KUKE
- CLRB Buy
- Analyst Count
- KUKE 0
- CLRB 2
- Target Price
- KUKE N/A
- CLRB $28.00
- AVG Volume (30 Days)
- KUKE 126.0K
- CLRB 1.4M
- Earning Date
- KUKE 04-15-2025
- CLRB 03-26-2025
- Dividend Yield
- KUKE N/A
- CLRB N/A
- EPS Growth
- KUKE N/A
- CLRB N/A
- EPS
- KUKE N/A
- CLRB N/A
- Revenue
- KUKE $14,784,158.00
- CLRB N/A
- Revenue This Year
- KUKE N/A
- CLRB N/A
- Revenue Next Year
- KUKE N/A
- CLRB N/A
- P/E Ratio
- KUKE N/A
- CLRB N/A
- Revenue Growth
- KUKE 10.48
- CLRB N/A
- 52 Week Low
- KUKE $0.23
- CLRB $0.22
- 52 Week High
- KUKE $4.07
- CLRB $4.45
- Technical
- Relative Strength Index (RSI)
- KUKE 34.52
- CLRB 46.10
- Support Level
- KUKE $0.36
- CLRB $0.26
- Resistance Level
- KUKE $0.50
- CLRB $0.35
- Average True Range (ATR)
- KUKE 0.06
- CLRB 0.03
- MACD
- KUKE -0.01
- CLRB 0.02
- Stochastic Oscillator
- KUKE 4.92
- CLRB 61.40
About KUKE Kuke Music Holding Limited
Kuke Music Holding Ltd provides classical music licensing, subscription, and education services in China. The company licenses its music content to online music entertainment platforms, such as Tencent Music Entertainment Group, digital music service providers, such as NetEase Cloud Music, as well as film and TV production companies, airlines, and smart hardware companies. Users can access the platform through the website, mobile app, and smart music devices.
About CLRB Cellectar Biosciences Inc.
Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. Its PDC therapeutic, iopofosine is a small-molecule PDC designed to provide targeted delivery of iodine-131 directly to cancer cells, while limiting exposure to healthy cells.